A triplet combination with Irinotecan (CPT-11) plus Oxaliplatin (L-OHP), continuous infusion 5-fluorouracil (5-FU) and Leucovorin (LV) (FOLFOXIRI) plus Cetuximab (C-225) as first line treatment in metastatic colorectal cancer (MCC) : A pilot phase II tria

The main objectives of this trial are to access the following: Objective Response Rate, Resectability Rates, Time to Tumor Progression (TTP), Median Overall Survival (mOS), Toxicity Profile, Pharmacogenomic Analysis, and Q-Twist analysis of Quality of Life.